^
    CANCER:

    Adrenal Cortex Carcinoma





    Show legend
    Group by Gene:
    Include preclinical:

    0
    DNA synthesis inhibitor
    streptozocin
    cisplatin
    1
    Steroid receptor inhibitor
    mitotane
    2
    PD1 inhibitor
    pembrolizumab
    3
    DNA synthesis inhibitor, Steroid receptor inhibitor
    mitotane + streptozocin
    4
    Topoisomerase II inhibitor, DNA synthesis inhibitor, Steroid receptor inhibitor
    cisplatin + etoposide IV + mitotane
    cisplatin + doxorubicin hydrochloride + etoposide IV + mitotane
    5
    Topoisomerase II inhibitor, DNA synthesis inhibitor
    cisplatin + etoposide IV
    cisplatin + doxorubicin hydrochloride + etoposide IV
    6
    Topoisomerase II inhibitor, Tubulin polymerization promoter, Steroid receptor inhibitor
    carboplatin + etoposide IV + mitotane
    carboplatin + doxorubicin hydrochloride + etoposide IV + mitotane
    7
    Topoisomerase II inhibitor, Tubulin polymerization promoter
    carboplatin + doxorubicin hydrochloride + etoposide IV
    carboplatin + etoposide IV
    8
    FGFR2 inhibitor, FGFR inhibitor, FGFR1 inhibitor, FGFR3 inhibitor, FGFR4 inhibitor
    erdafitinib
    9
    DNA topoisomerase inhibitor
    rubitecan
    teniposide
    		10
    Topoisomerase II inhibitor
    mitoxantrone
    doxorubicin hydrochloride
    11
    CDK4 inhibitor, CDK6 inhibitor, CDK9 inhibitor
    DSP-2033
    12
    CDK4 inhibitor, CDK6 inhibitor
    palbociclib
    13
    Topoisomerase II inhibitor, DNA inhibitor
    etoposide oral
    14
    DNA topoisomerase inhibitor, RNA synthesis inhibitor
    pirarubicin
    15
    Topoisomerase II inhibitor, DNA cross linking agent
    idarubicin hydrochloride
    16
    Topoisomerase II inhibitor, DNA intercalator
    daunorubicin
    17
    DNA intercalator
    aclarubicin
    18
    Aurora kinase inhibitor, Steroid receptor inhibitor
    mitotane + AMG 900
    19
    Aurora kinase inhibitor
    AMG 900
    20
    Multi-tyrosine kinase inhibitor
    cabozantinib capsule
    21
    EZH2 inhibitor
    EZH2 inhibitor
    22
    Chemotherapy
    EDP
    No biomarker
    MSI-H/dMMR
    RRM1 underexpression
    TMB-L
    MSH2 mutation
    FGFR3-TACC3 fusion
    TOP2A overexpression
    CDK1 overexpression
    CDK4 overexpression
    AURKB overexpression
    AURKA overexpression
    MET overexpression
    CDK2 overexpression
    EZH2 overexpression
    ASXL1 overexpression